ReviewAnnals of cardiothoracic surgery2026
The current state of isolated tricuspid valve surgery: how it complements transcatheter tricuspid valve interventions.
Review in Annals of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tricuspid valve insufficiency represents a prevalent health burden for many patients worldwide but remains highly undertreated. This is especially true for isolated tricuspid disease, where surgical intervention remains underutilized. Despite historically elevated periprocedural risk, isolated tricuspid valve surgery (iTVS) today can provide an effective and reliable solution to tricuspid disease. Successful iTVS requires careful evaluation of valve anatomy, pathophysiology, and patient risk profile. Available risk calculators can be useful tools in determining patient risk and surgical candidacy. Additionally, intervening within the treatment window before late right ventricular disease and distortion with end-organ damage is integral to success. The application of minimally invasive surgical approaches can further improve outcomes. Furthermore, tricuspid valve repair has been shown to improve long-term survival. For patients who are not candidates for surgery, transcatheter modalities have increased awareness and provide a promising treatment alternative for tricuspid regurgitation (TR) reduction and symptom control, albeit with limited durability data. Currently, surgical and transcatheter interventions address separate populations with distinct risk profiles. Hence, treatment success is dependent on matching the right patient with the right procedure. Patients with suitable anatomy and lower risk profiles should be considered for surgical approaches, particularly if repair may be feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.